Safety, tolerability, and pharmacokinetics of single and multiple doses of intravenous cixutumumab (IMC-A12), an inhibitor of the insulin-like growth factor-I receptor, administered weekly or every 2 weeks in patients with advanced solid tumors
Crossref DOI link: https://doi.org/10.1007/s10637-015-0217-7
Published Online: 2015-03-07
Published Print: 2015-04
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Higano, C. S.
Berlin, J.
Gordon, M.
LoRusso, P.
Tang, S.
Dontabhaktuni, A.
Schwartz, J. D.
Cosaert, J.
Mehnert, J. M.
Text and Data Mining valid from 2015-03-07
Version of Record valid from 2015-03-07
Article History
Received: 28 January 2015
Accepted: 5 February 2015
First Online: 7 March 2015